Observational studyBMC nephrology2025
Serum Kisspeptin levels in patients undergoing maintenance hemodialysis: a case-control study protocol.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHypogonadism is a highly prevalent complication in patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis (MHD), leading to a significant reduction in quality of life. The underlying pathophysiology involving the Hypothalamic-Pituitary-Gonadal (HPG) axis is complex and not fully understood. Kisspeptin is the master upstream regulator of the HPG axis, but its status and role in uremic hypogonadism remain unclear. This study aims to investigate serum Kisspeptin levels in MHD patients and explore their relationship with the HPG axis.
methodsThis single-center, observational, case-control study will be conducted at a university hospital in Shanghai. We will recruit approximately 78 patients with ESRD receiving stable MHD and 20 healthy volunteers as a control group. The primary outcome is the difference in serum Kisspeptin-54 levels between the two groups. Secondary outcomes include the correlation between Kisspeptin and other reproductive hormones (LH, FSH, testosterone, estradiol, and prolactin) and clinical symptoms of hypogonadism within the patient cohort. Blood samples will be collected pre-dialysis from patients and from controls in the morning. Serum Kisspeptin-54 will be measured by ELISA. The primary statistical analysis will be an Analysis of Covariance (ANCOVA) to compare Kisspeptin levels between groups, adjusting for age as a key confounder. DISCUSSION: This study is expected to clarify the status of circulating Kisspeptin in MHD patients. The findings may provide evidence for a state of central Kisspeptin resistance in uremia, offering new insights into the pathophysiology of uremic hypogonadism. Identifying Kisspeptin’s role could pave the way for novel diagnostic and therapeutic strategies for this common and debilitating condition.
trial registrationThis trial is registered with the Chinese Clinical Trial Registry (ChiCTR2500106627) (Registration Date 2025, Jul, 28th).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.